Overview

Rhoifolin (apigenin-7-O-neohesperidoside) is a flavone glycoside consisting of the aglycone apigenin linked to the disaccharide neohesperidose at the 7-position. It was originally isolated from the leaves of Rhus succedanea (Japanese wax tree) and has since been identified in numerous plant sources including citrus fruits (particularly grapefruit and bitter orange), grapes, artichoke, banana, tomatoes, and several traditional medicinal plants. As a glycosylated form of apigenin, rhoifolin exhibits distinct pharmacokinetic properties — the sugar moiety increases water solubility compared to free apigenin but also affects intestinal absorption and metabolism, with gut bacteria playing a role in deglycosylation and liberation of the active aglycone.

The pharmacological profile of rhoifolin reflects its structural relationship to apigenin while demonstrating unique activities of its own. Anti-inflammatory effects are mediated through inhibition of NF-kB activation, suppression of COX-2 and iNOS expression, and reduction of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. Rhoifolin also inhibits the NLRP3 inflammasome, a multiprotein complex increasingly recognized as a driver of chronic inflammatory conditions. Antioxidant activity is conferred through direct radical scavenging, chelation of pro-oxidant metal ions, and upregulation of endogenous antioxidant enzymes via Nrf2 pathway activation. Antimicrobial studies have demonstrated activity against various bacterial and fungal strains, with particular interest in its ability to inhibit bacterial biofilm formation — a property relevant to antibiotic-resistant infections.

Emerging research has focused on rhoifolin's anticancer potential. In vitro studies across breast, liver, lung, and colorectal cancer cell lines have shown growth-inhibitory effects mediated through induction of apoptosis, cell cycle arrest (particularly at G2/M phase), inhibition of PI3K/Akt/mTOR signaling, and suppression of epithelial-mesenchymal transition (EMT) — a process critical for cancer metastasis. Rhoifolin has also demonstrated the ability to sensitize cancer cells to conventional chemotherapeutic agents. While these findings remain preclinical, they contribute to the growing body of evidence supporting dietary flavonoids as chemopreventive agents. Rhoifolin shares its flavone backbone with related compounds including luteolin, baicalein, and chrysin, and its apigenin aglycone connects it to the broader apigenin research literature on neuroprotection and anxiolysis.

Mechanism of Action

Rhoifolin (apigenin-7-O-neohesperidoside) is a flavone glycoside found predominantly in Citrus species and other plants of the Rutaceae family. Its primary anti-inflammatory mechanism involves inhibition of the TLR4/NF-κB signaling pathway, as demonstrated in alcoholic liver disease models where rhoifolin reduced expression of TLR4, phosphorylated IκBα, and nuclear NF-κB p65, resulting in decreased production of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 (Mai et al., Frontiers in Pharmacology 2022). Rhoifolin also suppresses CYP2E1 expression, reducing ethanol-induced oxidative stress and hepatocyte apoptosis.

The anticancer properties of rhoifolin involve multiple molecular targets. It induces apoptosis in cancer cells through activation of the intrinsic mitochondrial pathway, upregulating pro-apoptotic proteins (Bax, cleaved caspase-3, cleaved caspase-9) while downregulating anti-apoptotic Bcl-2. Rhoifolin inhibits cancer cell proliferation by inducing cell-cycle arrest and suppressing PI3K/Akt/mTOR signaling. Molecular docking studies have confirmed strong binding affinity of rhoifolin to key target proteins including EGFR, VEGFR2, and TNF-α (Kilic et al., EXCLI Journal 2025). As a flavonoid glycoside, rhoifolin also exhibits potent antioxidant activity through direct scavenging of superoxide anion and hydroxyl radicals, chelation of transition metal ions, and upregulation of antioxidant enzymes via Nrf2 pathway activation. Additional pharmacological activities include inhibition of advanced glycation end-product (AGE) formation, aldose reductase inhibition relevant to diabetic complications, and antimicrobial effects against both gram-positive and gram-negative bacteria.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Rhoifolin

Common Side Effects

• Limited human clinical data; most safety information derived from in vitro and animal studies
• Mild gastrointestinal discomfort reported in supplemental use
• Potential for mild sedation due to reported anxiolytic properties
• Headache at higher doses

Serious Adverse Effects

• No serious adverse effects documented in humans due to paucity of clinical studies
• Animal studies show favorable toxicity profile at tested doses
• Theoretical risk of excessive anti-inflammatory or immunomodulatory effects at very high doses
• Unknown long-term safety profile

Contraindications

• Known allergy to rhoifolin or source plants (citrus fruits, Rhus species)
• Pregnancy and lactation (no safety data)
• Concurrent use of anticoagulants (flavonoid class may affect platelet function)

Drug Interactions

• Anticoagulants/antiplatelets: Theoretical antiplatelet effects common to flavonoids
• CYP450 substrates: Flavonoids may modulate hepatic enzyme activity; clinical significance for rhoifolin unknown
• Anti-inflammatory drugs: Potential additive anti-inflammatory effects

Population-Specific Considerations

• Research compound: Very early-stage research; not established as a commercial supplement
• Dietary exposure: Naturally present in citrus fruits and some vegetables at low levels; dietary amounts considered safe
• Clinical evidence: Insufficient data to establish dosing, safety thresholds, or therapeutic windows

Pharmacokinetic Profile